Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-12-03
2011-10-18
Wilson, James O. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S276000, C514S278000, C514S290000, C544S344000, C544S360000, C546S019000, C546S247000
Reexamination Certificate
active
08039471
ABSTRACT:
The present invention provides a compound of Formula I or Formula II:enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
REFERENCES:
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4973593 (1990-11-01), Brubaker
patent: 5157034 (1992-10-01), Bright et al.
patent: 5182288 (1993-01-01), Murray et al.
patent: 5494919 (1996-02-01), Morriello et al.
patent: 5536727 (1996-07-01), Witzel et al.
patent: 5610162 (1997-03-01), Witzel et al.
patent: 5763471 (1998-06-01), Fourtillan et al.
patent: 5872152 (1999-02-01), Brown
patent: 5892112 (1999-04-01), Levy et al.
patent: 5945430 (1999-08-01), Doll et al.
patent: 5968795 (1999-10-01), Dixon et al.
patent: 5972925 (1999-10-01), Hohlweg et al.
patent: 6071901 (2000-06-01), Dorwald et al.
patent: 6110913 (2000-08-01), Dorwald et al.
patent: 6114300 (2000-09-01), Bourdin et al.
patent: 6235764 (2001-05-01), Larson et al.
patent: 6239148 (2001-05-01), Dorwald et al.
patent: 6268379 (2001-07-01), Xue et al.
patent: 6372754 (2002-04-01), Kulagowski
patent: 6387371 (2002-05-01), Hudziak et al.
patent: 6414130 (2002-07-01), Doherty et al.
patent: 6429213 (2002-08-01), Xue et al.
patent: 6455472 (2002-09-01), Fischer et al.
patent: 6482838 (2002-11-01), Pratt
patent: 6489352 (2002-12-01), Bryans et al.
patent: 6500847 (2002-12-01), Van Zandt et al.
patent: 6528538 (2003-03-01), Zeiller et al.
patent: 6593344 (2003-07-01), Biedermann et al.
patent: 6608104 (2003-08-01), Noe
patent: 6653312 (2003-11-01), Auvin et al.
patent: 6713487 (2004-03-01), Yu et al.
patent: 6727247 (2004-04-01), Flohr et al.
patent: 6858626 (2005-02-01), Xue et al.
patent: 2002/0182702 (2002-12-01), Ruben et al.
patent: 2004/0006073 (2004-01-01), Dooley
patent: 2004/0034019 (2004-02-01), Tomlinson et al.
patent: 2004/0247602 (2004-12-01), Friedman et al.
patent: 2005/0113344 (2005-05-01), Li et al.
patent: 2005/0250789 (2005-11-01), Burns et al.
patent: 2007/0117809 (2007-05-01), Fridman
patent: 2007/0280943 (2007-12-01), Friedman et al.
patent: 2114178 (1994-07-01), None
patent: 006815 (2006-04-01), None
patent: 006964 (2006-06-01), None
patent: 0 431 197 (1991-06-01), None
patent: 550025 (1993-07-01), None
patent: 456183 (1995-10-01), None
patent: 937459 (1999-08-01), None
patent: 1415986 (2004-05-01), None
patent: 908986 (1962-10-01), None
patent: 1 596 030 (1981-08-01), None
patent: A-53-84947 (1978-07-01), None
patent: A-3-287562 (1991-12-01), None
patent: 07300460 (1995-11-01), None
patent: A-10-502067 (1998-02-01), None
patent: WO 93/23040 (1993-11-01), None
patent: WO 93/23041 (1993-11-01), None
patent: WO 94/17038 (1994-08-01), None
patent: WO 96/00727 (1996-01-01), None
patent: WO 96/11924 (1996-04-01), None
patent: WO 96/31470 (1996-10-01), None
patent: WO 96/31473 (1996-10-01), None
patent: WO 96/31474 (1996-10-01), None
patent: WO 96/31498 (1996-10-01), None
patent: WO 96/31500 (1996-10-01), None
patent: WO 96/31503 (1996-10-01), None
patent: WO 96/33176 (1996-10-01), None
patent: WO 98/08850 (1998-03-01), None
patent: WO 98/51665 (1998-11-01), None
patent: WO 98/57932 (1998-12-01), None
patent: WO 99/58528 (1999-11-01), None
patent: WO 99/65867 (1999-12-01), None
patent: WO 00/08046 (2000-02-01), None
patent: WO 00/17158 (2000-03-01), None
patent: WO 00/32193 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/35453 (2000-06-01), None
patent: WO 00/35876 (2000-06-01), None
patent: WO 00/43383 (2000-07-01), None
patent: WO 00/55143 (2000-09-01), None
patent: WO 00/75137 (2000-12-01), None
patent: WO 01/08669 (2001-02-01), None
patent: WO 01/00616 (2001-04-01), None
patent: WO 01/46166 (2001-06-01), None
patent: WO 01/58891 (2001-08-01), None
patent: WO 01/70673 (2001-09-01), None
patent: WO 01/98306 (2001-12-01), None
patent: WO 02/40481 (2002-05-01), None
patent: WO 02/055491 (2002-07-01), None
patent: WO 02/055516 (2002-07-01), None
patent: WO 02/074738 (2002-09-01), None
patent: WO 02/074754 (2002-09-01), None
patent: WO 02/096426 (2002-12-01), None
patent: WO 03/024456 (2003-03-01), None
patent: WO 03/031431 (2003-04-01), None
patent: WO 03/032914 (2003-04-01), None
patent: WO 03/051840 (2003-06-01), None
patent: WO 03/063845 (2003-08-01), None
patent: WO 03/076430 (2003-09-01), None
patent: WO 03/091220 (2003-11-01), None
patent: WO 03/092606 (2003-11-01), None
patent: WO 2004/024462 (2004-03-01), None
patent: WO 2004/018453 (2004-04-01), None
patent: WO 2004/034963 (2004-04-01), None
patent: WO 2004/037240 (2004-05-01), None
patent: WO 2004/043349 (2004-05-01), None
patent: WO 2004/056353 (2004-07-01), None
patent: WO 2004/065361 (2004-08-01), None
patent: WO 2004/089294 (2004-10-01), None
patent: WO 2004/104086 (2004-12-01), None
patent: WO 2005/037826 (2005-04-01), None
patent: WO 2005/117882 (2005-12-01), None
Official Action dated Feb. 20, 2008 in connection with Russian Pat. App. No. 2005136429/04(040664), three pages, translated.
Chemical Encyclopedic Dictionary, I.L. Knunyants, ed. “Sovetskaya Entisiklopedia,”, Moscow, 1983, pp. 130-131 (terms Getianks-Hydrogenolysis), translated.
Search Report from Eurasian Patent Office dated Jan. 30, 2008.
Office Action dated Apr. 8, 2008 in connection with U.S. Appl. No. 10/817,718.
Office Action dated Oct. 9, 2007 in connection with U.S. Appl. No. 10/817,718.
Amendment in Reply to Office Action dated Jan. 7, 2008 in connection with U.S. Appl. No. 10/817,718.
Non-final Office Action dated Mar. 20, 2007 in connection with U.S. Appl. No. 10/965,215.
Response to Office Action of Mar. 20, 2007 dated Jul. 19, 2007 in connection with U.S. Appl. No. 10/965,215.
Final Office Action dated Sep. 25, 2007 in connection with U.S. Appl. No. 10/965,215.
Amendment and Reply to Office Action dated Nov. 19, 2007, filed in connection with U.S. Appl. No. 10/965,215.
Amendment dated Jan. 14, 2008 filed in connection with U.S. Appl. No. 10/965,215.
Notice of Allowance and Notice of Allowability dated Jan. 17, 2008 in connection with U.S. Appl. No. 10/965,215.
Reply in Connection with a Request for Continued Examination dated Apr. 15, 2008 filed in connection with U.S. Appl. No. 10/965,215.
Office Action for corresponding Colombian Application No. 05-106.414, mailed Feb. 27, 2009, and based upon International Appl. No. PCT/US2004/012672, filed Apr. 23, 2004.
Amour et al., “The in Vitro Activity of ADAM-10 is Inhibited by TIMP-1 and TIMP-3,”FEBS Letters, 473(3):275-279, 2000.
Arribas et al., “Protein Ectodomain Shedding”,Chem. Rev., 102(12):4627-4638, 2002.
Babine at al., “Molecular Recognition of Protein minus sign Ligand Complexes: Applications to Drug Design”,Chem. Rev., 97,(5):1359-1472, 1997.
Baselga, et al. Phase II Study of weekly intravenous recombinant humanized anti-p185 Her2 monoclonal antibody in patients with HER2
eu-overexpressing metastic breast cancer. J. of Clin. Oncol. 14(3): 737-744, Mar. 1996.
Baselga et al., “Mechanism of Action of anti-HER2 Monoclonal Antibodies”,Annals of Oncology, 12/Suppl 1):S35-S41, 2001.
Baselga et al., “Mechanism of Action of Trastuzumab and Scientific Updated”,Seminars in Oncology, 28(5/Suppl 16):4-11, 2001.
Burns, D. M. et al. Bioorganic & Medicinal Chemistry Letters 18 (2008) 560-564.
Carney et al., “Potential Clinical Utility of Serum HER-2
eu Oncoprotein Concentrations in Patients with Breast Cancer”,Clinical Chemistry, 49(10):1579-1598, 2003.
Chandler et al., “Matrix Metalloproteinases Degrade Myelin Basic Protein”,Neuroscience Lett., 201(3):223-226, 1995.
Codony-Servat et al., “Cleavage of the HER2 Ectodomain is a Pervanadate-activable Process that is Inhibited by the tissue Inhibitor of Metalloproteases-1 in Brest Cancer Cells”,Cancer Research, 59(6):1196-1201, 1999.
Coussens et a
Metcalf Brian
Xu Meizhong
Yao Wenqing
Zhang Fenglei
Zhuo Jincong
Fish & Richardson P.C.
Incyte Corporation
Sackey Ebenezer O
Wilson James O.
LandOfFree
Aza spiro alkane derivatives as inhibitors of metalloproteases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aza spiro alkane derivatives as inhibitors of metalloproteases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aza spiro alkane derivatives as inhibitors of metalloproteases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4256355